• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Friday, August 7, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News

A new approach to target an ‘undruggable’ prostate cancer driver

Bioengineer by Bioengineer
March 23, 2017
in Science News
Reading Time: 1 min read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

(Michigan Medicine – University of Michigan) When small-molecule inhibitors proved elusive, researchers developed a novel strategy: Using large molecule peptides to target a common prostate cancer driver. It may provide a path for developing new therapies against a challenging target.

############

Story Source: Materials provided by Scienmag

Share12Tweet8Share2ShareShareShare2

Related Posts

How Somatic Mutations and Genome Mosaicism Shape Aging and Disease

August 7, 2026
Empire AI Beta Goes Online as Washington Adopts New York’s Hub Blueprint

Empire AI Beta Goes Online as Washington Adopts New York’s Hub Blueprint

August 7, 2026

Steatotic Liver Disease’s Global Spectrum Reveals a Dynamic Health Challenge

August 7, 2026

Targeting 4EBP1/HSP90β/Nrf2 Sensitizes β-Catenin-Mutant Liver Cancer to mTOR Inhibitors Through Ferroptosis

August 7, 2026
Please login to join discussion

POPULAR NEWS

  • How Somatic Mutations and Genome Mosaicism Shape Aging and Disease

    29 shares
    Share 12 Tweet 7
  • Empire AI Beta Goes Online as Washington Adopts New York’s Hub Blueprint

    29 shares
    Share 12 Tweet 7
  • Steatotic Liver Disease’s Global Spectrum Reveals a Dynamic Health Challenge

    29 shares
    Share 12 Tweet 7
  • Targeting 4EBP1/HSP90β/Nrf2 Sensitizes β-Catenin-Mutant Liver Cancer to mTOR Inhibitors Through Ferroptosis

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

How Somatic Mutations and Genome Mosaicism Shape Aging and Disease

Empire AI Beta Goes Online as Washington Adopts New York’s Hub Blueprint

Steatotic Liver Disease’s Global Spectrum Reveals a Dynamic Health Challenge

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 86 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.